BRISTOL MYERS SQUIBB
- Country
- 🇫🇷France
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
A Study to Assess the Bioavailability and Effect of Food of BMS-986419 Immediate-release Tablet Formulation in Healthy Adult Participants
- Conditions
- Interventions
- First Posted Date
- 2023-07-27
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 60
- Registration Number
- NCT05963932
- Locations
- 🇺🇸
Anaheim Clinical Trials, Anaheim, California, United States
A Study of Ozanimod in Pregnant Women With Ulcerative Colitis and Their Offspring
- Conditions
- First Posted Date
- 2023-07-20
- Last Posted Date
- 2023-07-20
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1182
- Registration Number
- NCT05953402
A Study to Assess the Effect of Danicamtiv on the Drug Levels of Midazolam in Participants With Stable Heart Failure
- Conditions
- Interventions
- First Posted Date
- 2023-07-19
- Last Posted Date
- 2024-04-04
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 13
- Registration Number
- NCT05952089
- Locations
- 🇺🇸
Research Integrity LLC, Owensboro, Kentucky, United States
🇺🇸Holy Cross Hospital, Fort Lauderdale, Florida, United States
🇺🇸Sinai Hospital Of Baltimore, Baltimore, Maryland, United States
ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions
- Conditions
- Interventions
- First Posted Date
- 2023-07-18
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 360
- Registration Number
- NCT05949684
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸Community Cancer Institute, Clovis, California, United States
🇺🇸Cancer and Blood Specialty Clinic, Los Alamitos, California, United States
A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome
- First Posted Date
- 2023-07-14
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 756
- Registration Number
- NCT05946941
- Locations
- 🇯🇵
Institute of Science Tokyo Hospital, Bunkyo-ku, Tokyo, Japan
🇩🇪Charite University Hospitals, Berlin, Germany
🇵🇹Instituto Portugues de Reumatologia, Lisboa, Portugal
Mavacamten Pregnancy Surveillance Program
- Conditions
- Interventions
- First Posted Date
- 2023-07-11
- Last Posted Date
- 2023-11-28
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 20
- Registration Number
- NCT05939700
- Locations
- 🇺🇸
The Mavacamten Pregnancy Surveillance Program, PPD Inc, Wilmington, North Carolina, United States
A Study to Assess the Effect of BMS-986419 on the Single Dose Drug Levels of Probe Substrates in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2023-07-06
- Last Posted Date
- 2023-10-30
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 22
- Registration Number
- NCT05932277
- Locations
- 🇺🇸
ICON Lenexa, Lenexa, Kansas, United States
A Study to Assess the Effect of Multiple Doses of Itraconazole, Gemfibrozil, or Carbamazepine on BMS-986278 in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2023-07-06
- Last Posted Date
- 2023-10-30
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 47
- Registration Number
- NCT05932303
- Locations
- 🇨🇦
Local Institution - 0001, Québec, CA, Canada
Expanded Access for Repotrectinib
- First Posted Date
- 2023-07-03
- Last Posted Date
- 2023-07-03
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT05926232
A Study to Assess the Effect of Phenytoin on the Drug Levels of Afimetoran and the Effect of Afimetoran on the Drug Levels of Midazolam
- Conditions
- Interventions
- First Posted Date
- 2023-06-13
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 65
- Registration Number
- NCT05901714
- Locations
- 🇺🇸
Local Institution - 0001, Miami, Florida, United States